🚀 VC round data is live in beta, check it out!
Avidity Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Avidity Biosciences and similar public comparables like Eli Lilly, Johnson & Johnson, AbbVie, Roche and more.
Avidity Biosciences Overview
About Avidity Biosciences
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Founded
2025
HQ
Employees
391
Website
Sectors
Financials (FY)
Market Cap
—
Avidity Biosciences Stock Performance
Avidity Biosciences has current market cap of —.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| — | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAvidity Biosciences Valuation Multiples
Avidity Biosciences Financial Valuation Multiples
As of April 24, 2026, Avidity Biosciences has market cap of —.
Equity research analysts estimate Avidity Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 |
|---|
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Avidity Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Avidity Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Avidity Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Eli Lilly | XXX | XXX | XXX | XXX | XXX | XXX |
| Johnson & Johnson | XXX | XXX | XXX | XXX | XXX | XXX |
| AbbVie | XXX | XXX | XXX | XXX | XXX | XXX |
| Roche | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Avidity Biosciences M&A Activity
Avidity Biosciences acquired XXX companies to date.
Last acquisition by Avidity Biosciences was on XXXXXXXX, XXXXX. Avidity Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Avidity Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAvidity Biosciences Investment Activity
Avidity Biosciences invested in XXX companies to date.
Avidity Biosciences made its latest investment on XXXXXXXX, XXXXX. Avidity Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Avidity Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Avidity Biosciences
| When was Avidity Biosciences founded? | Avidity Biosciences was founded in 2025. |
| Where is Avidity Biosciences headquartered? | Avidity Biosciences is headquartered in United States. |
| How many employees does Avidity Biosciences have? | As of today, Avidity Biosciences has over 391 employees. |
| Is Avidity Biosciences publicly listed? | Yes, Avidity Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Avidity Biosciences? | Avidity Biosciences trades under RNAM ticker. |
| When did Avidity Biosciences go public? | Avidity Biosciences went public in 2026. |
| Who are competitors of Avidity Biosciences? | Avidity Biosciences main competitors are Eli Lilly, Johnson & Johnson, AbbVie, Roche. |
| Is Avidity Biosciences profitable? | No, Avidity Biosciences is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.